Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Immunovant Inc (IMVT)

Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,859,152
  • Shares Outstanding, K 146,180
  • Annual Sales, $ 0 K
  • Annual Income, $ -259,340 K
  • 60-Month Beta 0.67
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.12
Trade IMVT with:

Options Overview Details

View History
  • Implied Volatility 70.68% ( +9.22%)
  • Historical Volatility 48.42%
  • IV Percentile 35%
  • IV Rank 10.64%
  • IV High 265.97% on 09/25/23
  • IV Low 47.43% on 06/17/24
  • Put/Call Vol Ratio 0.07
  • Today's Volume 114
  • Volume Avg (30-Day) 1,087
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 22,269
  • Open Int (30-Day) 24,674

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.52
  • Number of Estimates 7
  • High Estimate -0.39
  • Low Estimate -0.58
  • Prior Year -0.47
  • Growth Rate Est. (year over year) -10.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.67 +7.01%
on 06/10/24
31.81 -17.01%
on 05/29/24
-2.02 (-7.11%)
since 05/28/24
3-Month
24.67 +7.01%
on 06/10/24
32.40 -18.52%
on 04/05/24
-5.91 (-18.29%)
since 03/28/24
52-Week
18.16 +45.36%
on 07/07/23
45.58 -42.08%
on 01/09/24
+7.26 (+37.93%)
since 06/28/23

Most Recent Stories

More News
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond

These five biotech companies could have a lot of room to run.

AMGN : 312.45 (-0.40%)
ARGX : 430.04 (-3.35%)
BGNE : 142.67 (-2.00%)
CRSP : 54.01 (-2.47%)
IMVT : 26.40 (+1.54%)
Why Immunovant Stock Is Bolting Higher Today

The company may have best-in-class autoimmune disease therapy under its roof.

ARGX : 430.04 (-3.35%)
JNJ : 146.16 (+0.25%)
IMVT : 26.40 (+1.54%)
ROIV : 10.57 (unch)
Stocks Tumble as Confidence in the U.S. Economic Outlook Wanes

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -1.47%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed...

$SPX : 5,460.48 (-0.41%)
SPY : 544.22 (-0.39%)
$DOWI : 39,118.86 (-0.12%)
DIA : 391.13 (-0.11%)
$IUXX : 19,682.87 (-0.54%)
QQQ : 479.11 (-0.52%)
CTAS : 700.26 (-1.60%)
AMZN : 193.25 (-2.32%)
AAPL : 210.62 (-1.63%)
GOOGL : 182.15 (-1.76%)
MSFT : 446.95 (-1.30%)
META : 504.22 (-2.95%)
Why Shares of Immunovant Are Soaring on Tuesday

Immunovant sees strong potential for an autoimmune disorder therapy.

ROIV : 10.57 (unch)
RJF : 123.61 (+1.66%)
IMVT : 26.40 (+1.54%)
Stocks Retreat on U.S. Economic Concerns

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -1.01%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.78%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.07%....

$SPX : 5,460.48 (-0.41%)
SPY : 544.22 (-0.39%)
$DOWI : 39,118.86 (-0.12%)
DIA : 391.13 (-0.11%)
$IUXX : 19,682.87 (-0.54%)
QQQ : 479.11 (-0.52%)
CTAS : 700.26 (-1.60%)
AMZN : 193.25 (-2.32%)
GOOGL : 182.15 (-1.76%)
AAPL : 210.62 (-1.63%)
MSFT : 446.95 (-1.30%)
META : 504.22 (-2.95%)
These 2 Biotech Stocks Are Bucking a Down Market Tuesday

Stock index futures pointed to a lower open on Wall Street Tuesday morning.

IMVT : 26.40 (+1.54%)
ROIV : 10.57 (unch)
Markets Today: Stocks Slip on Additional Hawkish Fed Comments

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.41%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.44%. Stock index futures this morning are moderately lower. Stock markets...

ESU24 : 5,535.25 (+0.25%)
NQU24 : 19,980.50 (+0.27%)
TSLA : 197.88 (+0.23%)
UNFI : 13.10 (+1.55%)
THO : 93.45 (+1.74%)
OLN : 47.15 (-1.01%)
COTY : 10.02 (-0.20%)
FLS : 48.10 (+0.52%)
EW : 92.37 (-1.04%)
DKNG : 38.17 (+2.86%)
IMVT : 26.40 (+1.54%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Immunovant, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

IMVT : 26.40 (+1.54%)
Why Immunovant Stock Is Skyrocketing This Week

The drugmaker announced a $75 million public offering.

IMVT : 26.40 (+1.54%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing

Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all...

ONCY : 0.9900 (-1.98%)
ONC.TO : 1.35 (-2.17%)
SNTI : 0.2760 (-13.48%)
INBX : 14.17 (+0.78%)
IMVT : 26.40 (+1.54%)
AUTL : 3.48 (+4.50%)
BMY : 41.53 (+0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The...

See More

Key Turning Points

3rd Resistance Point 27.78
2nd Resistance Point 27.18
1st Resistance Point 26.79
Last Price 26.40
1st Support Level 25.80
2nd Support Level 25.20
3rd Support Level 24.81

See More

52-Week High 45.58
Fibonacci 61.8% 35.11
Fibonacci 50% 31.87
Fibonacci 38.2% 28.64
Last Price 26.40
52-Week Low 18.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar